Venturi Wealth Management’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-18,889
Closed -$394K 1084
2024
Q4
$394K Sell
18,889
-5,009
-21% -$110K 0.02% 377
2024
Q3
$583K Buy
23,898
+102
+0.4% +$2.73K 0.03% 263
2024
Q2
$598K Sell
23,796
-134
-0.6% -$3.8K 0.04% 253
2024
Q1
$716K Buy
23,930
+155
+0.7% +$4.55K 0.05% 220
2023
Q4
$757K Sell
23,775
-715
-3% -$22.4K 0.05% 215
2023
Q3
$864K Buy
24,490
+51
+0.2% +$1.94K 0.07% 182
2023
Q2
$929K Buy
24,439
+30
+0.1% +$1.2K 0.07% 168
2023
Q1
$922K Buy
24,409
+2,140
+10% +$82.3K 0.08% 171
2022
Q4
$944K Sell
22,269
-4,934
-18% -$203K 0.08% 168
2022
Q3
$874K Buy
27,203
+436
+2% +$15.3K 0.08% 154
2022
Q2
$870K Buy
26,767
+5,747
+27% +$186K 0.08% 158
2022
Q1
$760K Buy
21,020
+222
+1% +$7.62K 0.06% 199
2021
Q4
$823K Buy
20,798
+1,195
+6% +$49.8K 0.06% 204
2021
Q3
$857K Buy
19,603
+873
+5% +$39.2K 0.07% 181
2021
Q2
$765K Buy
18,730
+842
+5% +$32.5K 0.07% 196
2021
Q1
$587K Buy
17,888
+3,348
+23% +$126K 0.06% 216
2020
Q4
$591K Buy
14,540
+1,140
+9% +$42.6K 0.06% 207
2020
Q3
$491K Buy
13,400
+57
+0.4% +$2.06K 0.06% 207
2020
Q2
$452K Buy
+13,343
New +$364K 0.06% 197

Other funds holding GMAB

Venturi Wealth Management's GMAB Position: Q1 2025 in Review

Venturi Wealth Management sold out of Genmab (GMAB) in Q1 2025, closing a stake of 18,889 shares — an estimated $394K sold.

Venturi Wealth Management first reported a position in GMAB in Q2 2020 and held it in 19 quarters. The position peaked at $944K in Q4 2022. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

  • Venturi Wealth Management reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 18,889 Genmab shares in Q1 2025, an estimated $394K.
  • Venturi Wealth Management first reported a position in Genmab in Q2 2020 and held it in 19 quarters.
  • Venturi Wealth Management's Genmab position peaked at $944K in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.